From: Some psychiatric comorbidity among patients with substance abuse disorder related to pregabalin
Variable | (n = 83) | ||
---|---|---|---|
No. | % | ||
Duration (months) | Median (IQR) | 24 (12–36) | |
Start dose (mg) | Median (IQR) | 300 (150–750) | |
Maximum dose (mg) | Median (IQR) | 1500 (750–1500) | |
Daily dose (mg) | Median (IQR) | 1500 (750–1500) | |
Last dose since (day) | Median (IQR) | 15 (4–30) | |
Course | Continuous | 72 | 86.7 |
Intermittent | 11 | 13.3 | |
Type of addiction | Mono | 17 | 20.5 79.5 |
Poly | 66 | ||
Causes of abuse | Replacement of heroin | 49 | 59 |
Due to pain | 40 | 48.2 | |
Replacement of tramadol | 26 | 31.3 | |
For its euphoric and analgesic effect | 8 | 9.6 | |
Causes of seeking treatment | Family causes | 67 | 80.7 |
Medical causes | 14 | 16.9 | |
Economic causes | 2 | 2.4 | |
Urine test | −ve | 60 | 72.3 |
+ve | 23 | 27.7 |